1 – 8 of 8
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction—Outcomes at two years
2024) In Cardiovascular Revascularization Medicine(
- Contribution to journal › Article
- 2023
-
Mark
Rationale and design of BROKEN-SWEDEHEART : a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome
(
- Contribution to journal › Article
-
Mark
Prognostic Value of Early Sustained Ventricular Arrhythmias in ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention : A Substudy of VALIDATE-SWEDEHEART Trial
(
- Contribution to journal › Article
- 2022
-
Mark
Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries
(
- Contribution to journal › Article
- 2021
-
Mark
Uninterrupted Oral Anticoagulant Therapy in Patients Undergoing Unplanned Percutaneous Coronary Intervention
(
- Contribution to journal › Article
-
Mark
Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction
(
- Contribution to journal › Article
- 2019
-
Mark
Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction
(
- Contribution to journal › Article
-
Mark
Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management : A prespecified subgroup analysis from VALIDATE-SWEDEHEART
(
- Contribution to journal › Article